Periodic, partial inhibition of IκB kinase β-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 349-360

  Gillooly, Kathleen M ^a   Pattoli, Mark A ^a   Taylor, Tracy L ^a   Chen, Laishun ^a   Cheng, Lihong ^a   Gregor, Kurt R ^a   Whitney, Gena S ^a   Susulic, Vojkan ^a   Watterson, Scott H ^a   Kempson, James ^a   Pitts, William J ^a   Booth Lute, Hollie ^a   Yang, Guchen ^a   Davies, Paul ^a   Kukral, Daniel W ^a   Strnad, Joann ^a   McIntyre, Kim W ^a   Darienzo, Celia J ^a   Salter Cid, Luisa ^a   Yang, Zheng ^a   Wang Iverson, David B ^a   Burke, James R ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY N [[6 [1 METHYL 4(METHYLAMINO) 1,6 DIHYDROIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 7 YL]PYRIDIN 2 YL]METHYL]ACETAMIDE; ACETAMIDE DERIVATIVE; BMS 066; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN P19; PROTEIN P40; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; JOINT DESTRUCTION; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH17 CELL; TREATMENT DURATION;

ACETAMIDES; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CELL PROLIFERATION; COLLAGEN; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; IMMUNOGLOBULINS; JOINTS; JURKAT CELLS; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; OSTEOCLASTS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350443427     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156018     Document Type: Article

References (37)

1. Ammann JU, Haag C, Kasperczyk H, Debatin KM, and Fulda S (2009) Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int J Cancer 124:1301-1311.
2. Beaulieu F, Ouellet C, Ruediger EH, Belema M, Qiu Y, Yang X, Banville J, Burke JR, Gregor KR, MacMaster JF, et al. (2007) Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorg Med Chem Lett 17:1233-1237. (Pubitemid 46251488)
3. Belema M, Bunker A, Nguyen VN, Beaulieu F, Ouellet C, Qiu Y, Zhang Y, Martel A, Burke JR, McIntyre KW, et al. (2007) Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors. Bioorg Med Chem Lett 17:4284-4289. (Pubitemid 47021393)
4. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chilpala E, and Guy M (1999) Animal models of arthritis: relevance to human disease. Toxicol Pathol 27:134-142. (Pubitemid 29075759)
5. Burke JR, Miller KR, Wood MK, and Meyers CA (1998) The multisubunit IκB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IκBα. J Biol Chem 273:12041-12046. (Pubitemid 28240561)
6. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, Klaus GG, Johnston LH, and Ley SC (2002) CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J 21:5375-5385. (Pubitemid 35231017)
7. Ghosh S and Karin M (2002) Missing pieces in the NF-κB puzzle. Cell 109:S81-S96.
8. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, and Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633-640.
9. Gross S and Piwnica-Worms D (2005) Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2:607-614. (Pubitemid 41086852)
10. Ivanov S and Lindén A (2009) Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 30:95-103.
11. Kempson J, Guo J, Das J, Moquin RV, Spergel SH, Watterson SH, Langevine CM, Dyckman AJ, Pattoli M, Burke JR, et al. (2009b) Synthesis, initial SAR and biological evaluation of 1,6-dihyrdoimidazo[4,5,-d]pyrrolor[2,3-b]pyridine-4- amine derived inhibitors of IκB kinase. Bioorg Med Chem Lett 19:2646-2649.
12. Kempson J, Spergel SH, Guo J, Quesnelle C, Gill P, Belanger D, Dyckman AJ, Li T, Watterson SH, Langevine CM, et al. (2009a) Novel tricyclic inhibitors of IκB kinase. J Med Chem 52:1994-2005.
13. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, and CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356:580-592.
14. Kumins NH, Hunt J, Gamelli RL, and Filkins JP (1996) Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats. Shock 5:385-388. (Pubitemid 126812848)
15. Li Y, Sedwick CE, Hu J, and Altman A (2005) Role for protein kinase Cθ (PKCθ) in TCR/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-κB activation. J Biol Chem 280:1217-1223.
16. Liptay S, Schmid RM, Nabel EG, and Nabel GJ (1994) Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation. Mol Cell Biol 14:7695-7703. (Pubitemid 24373521)
17. Liu XK, Lin X, and Gaffen SL (2004) Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J. Biol. Chem. 279:52762-52771. (Pubitemid 39656652)
18. Lubberts E (2008) IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41:84-91.
19. MacMaster JF, Dambach DM, Lee DB, Berry KK, Qiu Y, Zusi FC, and Burke JR (2003) An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res 52:508-511. (Pubitemid 38058225)
20. Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, et al. (2009) A novel, highly selective, tight binding IκB kinase-2 (IKK-2) inhibitor: A tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-κB pathway in arthritis-relevant cells and animal models. J Pharmacol Exp Ther 329:14-25.
21. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, and Cua DJ (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10:314-324.
22. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, Zhou XD, Qiu Y, Zusi FC, and Burke JR (2003) A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 48:2652-2659. (Pubitemid 37129443)
23. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, et al. (2009) Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4:579-587.
24. Mise-Omata S, Kuroda E, Niikura J, Yamashita U, Obata Y, and Doi TS (2007) A proximal κB site in the IL-23 p19 promoter is responsible for RelA- and c-Rel-dependent transcription. J Immunol 179:6596-6603.
25. Ogawa K, Funaba M, and Tsujimoto M (2008) Suppression of NF-κB and IRF-1-induced transcription of the murine IL-12 p40 by transforming growth factor-β Smad pathway in macrophages. Mol Cell Biochem 308:9-15. (Pubitemid 351167839)
26. Pattoli MA, MacMaster JF, Gregor KR, and Burke JR (2005) Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage explants by an inhibitor of IκB kinase through suppression of metalloproteinase expression. J Pharmacol Exp Ther 315:382-388.
27. Pitts WJ, Kempson J, Guo J, Das J, Langevine CM, Spergel SH, and Watterson SH (2006) inventors; Bristol-Myers Squibb Company, assignee. 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same as inhibitors of IKK enzyme activity. World patent WO/2006/122137. 2006 May 9.
28. Pitts WJ and Kempson J (2008) Advances in the discovery of IκB kinase inhibitors. Annu Rep Med Chem 43:155-170.
29. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, and Roshak AK (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3- thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312:373-381. (Pubitemid 40096491)
30. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, and Karin M (2005) IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677-1687. (Pubitemid 40721011)
31. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, and Ustekinumab Crohn's Disease Study Group (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135:1130-1141.
32. Schomer-Miller B, Higashimoto T, Lee YK, and Zandi E (2006) Regulation of IκB kinase (IKK) complex by IKKγ-dependent phosphorylation of the T-loop and C terminus of IKKβ. J Biol Chem 281:15268-15276. (Pubitemid 43855116)
33. Schopf L, Savinainen A, Anderson K, Kujawa J, DuPont M, Silva M, Siebert E, Chandra S, Morgan J, Gangurde P, et al. (2006) IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 54:3163-3173. (Pubitemid 44622087)
34. Schuna AA (2007) Rituximab for the treatment of rheumatoid arthritis. Pharmacotherapy 27:1702-1710.
35. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, and Roth J (2004) Transcriptional profiling of IKK2/NF-κB- and p38 MAP kinase-dependent gene expression in TNF-α-stimulated primary human endothelial cells. Blood 103:3365-3373. (Pubitemid 38525666)
36. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, Lamping N, Schumann RR, Thieringer R, Fenton MJ, et al. (1997) Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 186:2051-2056. (Pubitemid 28013690)
37. Yang J, Amiri KI, Burke JR, Schmid JA, and Richmond A (2006) BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12:950-960. (Pubitemid 43259878)